ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO2483

COVID-19 in Kidney Transplant Recipients: Experience from a Large Health System in Louisiana

Session Information

Category: Transplantation

  • 1902 Transplantation: Clinical

Authors

  • Torres Ortiz, Aldo E., Ochsner Health System, New Orleans, Louisiana, United States
  • Walker, Joseph B., Ochsner Health System, New Orleans, Louisiana, United States
  • Velez, Juan Carlos Q., Ochsner Health System, New Orleans, Louisiana, United States
  • Garces, Jorge C., Ochsner Health System, New Orleans, Louisiana, United States

Group or Team Name

  • Ochsner Nephrology
Background

Infections are an important cause of morbidity and mortality among kidney transplant recipients. The novel Coronavirus Disease 2019 (COVID-19) has affected all kinds of populations world-wide. However, the role of immunosuppression in the outcomes of these patients is not well understood.

Methods

We conducted a retrospective study in kidney transplant recipients from a single health system that were diagnosed with COVID-19 based on a positive real-time reverse transcription polymerase chain reaction test for SARS-CoV-2 RNA between 03/01/2020 and 04/30/2020. We compared them with affected patients without a kidney transplant and without any kind of immunosuppressive medication (control). We examined the rates of hospitalization, intensive-care unit (ICU) admission, acute kidney injury (AKI) and mortality as outcome measures.

Results

A total of 8473 patients were diagnosed with COVID-19 within our Health System within the study period. Thirty-three (0.4%) were kidney transplant recipients. Sixteen of the 33 (48%) were admitted to the hospital (median age of 56, 68% males, 93% African American) vs 2201 admissions (25%) for the control group (median age 66, 48% males, 65% African-American), i.e., a significantly greater risk for hospitalization for transplant recipients (p = 0.002). Percentage of patients with hypertension in the transplant group was numerically higher (93% vs 80%, p = 0.06), as well as the number of ICU admissions (43% vs 28%, p = 0.055). AKI was more common in transplant patients (81% vs 33.8% p<0.0001). No difference in mortality was observed (31 vs 24%, p = 0.34). Among transplant patients, those hospitalized were more likely to be on prednisone (75% vs 35%, p = 0.025) and had a post-transplant graft life of 7.9 years compared to 5.5 years for those not hospitalized, p 0.08).

Conclusion

Kidney transplant recipients affected with COVID-19 exhibited a greater incidence of hospitalization, AKI and a trend for more ICU admissions. Use of immunosuppression with prednisone was associated with greater risk for hospitalization